CytoDyn (CYDY) Asset Utilization Ratio (2021 - 2022)

CytoDyn (CYDY) posted Asset Utilization Ratio of 0.0 for Q2 2022, up 80.96% on a QoQ basis from 0.0 in Q1 2022.

CytoDyn (CYDY) Asset Utilization Ratio (2021 - 2022) Analysis & Trends

CytoDyn's Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q2 2022.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.0 in Q2 2022, while the trailing twelve-month figure through May 2022 was 0.0 (changed N/A YoY) and the FY2022 annual result came in at 0.0, changed N/A from the prior year.
Asset Utilization Ratio was 0.0 for Q2 2022 at CytoDyn, up from 0.0 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.0 in Q2 2022 and bottomed at 0.0 in Q3 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.69
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.37
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	CytoDyn	267.79 Mn	267.79 Mn	-	-

Historic Data

Download Data

Date	Value
May 31, 2022	0.00
Feb 28, 2022	0.00
Nov 30, 2021	0.00
Aug 31, 2021	0.00